Publication | Closed Access

A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer

Erα RatioBreast OncologyMedicineHigh ArPharmacologyBreast CancerPharmacotherapyErα-positive Breast CancerCancer TreatmentOncologyRadiation OncologyCancer ResearchEndocrine-related Cancer